The Trump administration has terminated HIV funding for South Africa, effective immediately. The decision cuts off billions of rand in annual support from the President’s Emergency Plan for AIDS Relief (PEPFAR), a programme that has provided antiretroviral therapy to over 5 million South Africans since 2003.
The move, framed as part of a broader re-evaluation of foreign aid, disrupts a carefully calibrated public health system. South Africa bears the highest HIV burden globally, with 7.8 million people living with the virus. PEPFAR funds have covered roughly 17% of the country’s HIV response, including drug procurement, clinic staffing, and community outreach programmes.
The consequences are stark. Without these funds, treatment interruptions are inevitable. The World Health Organization warns that even short gaps in antiretroviral therapy lead to viral rebound, increasing the risk of drug resistance and transmission. Modelling by the South African Medical Research Council suggests that a six-month funding lapse could reverse a decade of progress, adding 100,000 new infections and 50,000 AIDS-related deaths.
This decision is not an isolated event. It signals a systemic shift in US foreign policy, prioritising domestic interests over global health commitments. The Global Fund to Fight AIDS, Tuberculosis and Malaria, which relies heavily on US contributions, faces similar uncertainty. Other high-burden nations, including Nigeria and Uganda, are bracing for potential cuts.
The timing is particularly treacherous. South Africa is still recovering from the COVID-19 pandemic, which strained its healthcare system and disrupted HIV services. Now, clinics that serve the poorest communities, where HIV prevalence often exceeds 25%, may close their doors.
There is precedent for this scale of disruption. In 2018, when the US temporarily halted funding to the UN Relief and Works Agency, health outcomes in Palestinian territories deteriorated rapidly. But PEPFAR’s withdrawal is on a different magnitude: it directly affects millions of people dependent on continuous medication.
The South African government has stated it cannot immediately fill the funding gap. The national health budget is already stretched, with competing demands from tuberculosis, maternal mortality, and a growing non-communicable disease burden. Philanthropic organisations like the Gates Foundation have signalled interest, but their resources are limited.
The data tell a sobering story. Since 2005, HIV incidence in South Africa has fallen by 60% due to widespread treatment. That trajectory is now at risk. The number of people receiving antiretroviral therapy through public clinics, currently 4.5 million, will likely drop sharply.
The rationale for the cut, as presented by the administration, centres on financial accountability. But the real-world cost is measured in human lives. For every year that treatment is delayed, an individual’s risk of developing AIDS increases by 30%. The economic cost is equally severe: lost productivity, orphaned children, and overwhelmed hospitals.
The international community must respond. The European Union and the African Union have already expressed concern. But without rapid replacement funding, the damage will cascade. This is not a budget adjustment. It is a fracture in the global health architecture, one that will take years to repair.
The planet is warming. The biosphere is collapsing. And now, a preventable disease is being allowed to resurge because of political calculus. The calm urgency of this moment cannot be overstated. We are watching a public health system dismantled in real time, and the consequences will be measured in the bodies that do not receive their next dose of medication.
